Oxford Immunotec closes financing round
Oxford – Oxford Immunotec has closed a financing round for a27 million. The funding of the British company marks the largest financing for a diagnostics specialist in Europe in the past two years. It was co-led by new investors Clarus Ventures, Wellington Partners with Kuwait-based National Technology Enterprises Company, along with Immunotec’s current investors. The company will use the funding to prepare for the market launch for its lead product T-Spot, a blood-based test for tuberculosis.